Updated: November 10, 2020 at 8:25:43
Pfizer says an initial look at its vaccine data suggests that shots may be 90% effective in preventing Covid-19, but that doesn’t mean there is no vaccine imminent. (Ryan Reminders: By Canadian Press VAP)
Is the main route to India Monday’s announcement by Pfizer The US pharma giant has decided to discuss with regulatory authorities worldwide.
In August Gust, the Indian Express first reported that the Government of India had held an “initial meeting” with representatives of Pfizer’s Indian subsidiary a few days after Pfizer released the trial phase 1 data of its candidate for the novel coronavirus vaccine, stating that the response was overwhelming. .
Pfizer has identified five facilities around the world, including the United States and Germany, for its Covid-19 vaccine. Top government sources had earlier confirmed to The Indian Express that while no agreement had been reached with the government by Pfizer, and no manufacturing facility had been identified, a “fill and finish” option was likely to emerge. થયેલ Express Express is now on Telegram
Pfizer said it would produce 100 million doses by the end of the 20 million years of vaccination, and possibly more than 1.2 billion doses by the end of 2021. It has announced agreements to supply vaccines to countries including the United States and the United States. Kingdom, Japan and Canada.
If the company (and its partner, the German biotech firm Bioentech) had decided to contact the Indian regulatory authorities, the main issue that needs to be addressed is the cold chain. Pfizer’s mRNA vaccine candidate needs storage and shipping in sub-zero temperature conditions.
A sub-group on vaccine administration, formed by a high-level expert group in India, has started mapping cold storage facilities across the country, available with the food processing industry. The 28,000-unit cold storage network, utilized by the country’s universal immunization program, currently handles temperate in the range of 2-8 C.
. The Indian Express (P) Ltd.
.
